Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)-A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)-

被引：0
|
作者：
Park, Y.
Akabane, H.
Watanabe, T.
Takahashi, M.
Sagara, Y.
Nishimura, R.
Tsurutani, J.
Takashima, T.
Fujisawa, T.
Hozumi, Y.
Uemura, Y.
Mukai, H.
机构：
[1] Tohoku Med & Pharmaceut Univ, Fac Med, Sendai, Miyagi, Japan
[2] Hokkaido PWFAC Asahikawa Kosei Gen Hosp, Asahikawa, Hokkaido, Japan
[3] Sendai Med Ctr, Natl Hosp Org, Sendai, Miyagi, Japan
[4] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Hakuaikai Med Corp Sagara Hosp, Kagoshima, Japan
[6] Kumamoto Shinto Gen Hosp, Kumamoto, Japan
[7] Kindai Univ, Fac Med, Osakasayama, Japan
[8] Osaka City Univ, Grad Sch Med, Osaka, Japan
[9] Gunma Prefectural Canc Ctr, Ota, Japan
[10] Univ Tsukuba Hosp, Ibaraki Prefectural Cent Hosp, Kasama, Ibaraki, Japan
[11] Univ Tokyo Hosp, Tokyo, Japan
[12] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-14-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-07
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results
    Kim, Mi-Jung
    Kong, Sun-Young
    Nam, Byung-Ho
    Kim, Sohee
    Park, Young-Iee
    Park, Sook Ryun
    PHARMACOGENETICS AND GENOMICS, 2018, 28 (01): : 23 - 30
  • [42] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
    Hong, Yong Sang
    Park, Young Suk
    Lim, Ho Yeong
    Lee, Jeeyun
    Kim, Tae Won
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Chung, Ik-Joo
    Cho, Sang-Hee
    Lee, Kyung Hee
    Shin, Sang Joon
    Kang, Hye Jin
    Shin, Dong Bok
    Jo, Sook Jung
    Lee, Jae Won
    LANCET ONCOLOGY, 2012, 13 (11): : 1125 - 1132
  • [43] Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18
    Schwitter, Michael
    Zaman, Khalil
    Jerusalem, Guy
    Cazzaniga, Marina
    Greil, Richard
    Ursula, Ursula Strub
    Mueller, Andreas
    Nussbaum, Catrina Uhlmann
    Auteri, Agnes
    Rothgiesser, Karin
    Dietrich, Daniel
    Ruhstaller, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [44] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.
    Park, Young Suk
    Kim, Seung
    Hong, Yong Sang
    Lim, Ho Yeong
    Lee, Jeeyun
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Chung, Ik-Joo
    Cho, Sang-Hee
    Lee, Kyung Hee
    Shin, Sang Joon
    Kang, Hye Jin
    Shin, Dong Bok
    Jo, Sook Jung
    Lee, Jae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Yoshito Komatsu
    Chikashi Ishioka
    Ken Shimada
    Yasuhide Yamada
    Makio Gamoh
    Atsushi Sato
    Tatsuro Yamaguchi
    Satoshi Yuki
    Satoshi Morita
    Shin Takahashi
    Rei Goto
    Minoru Kurihara
    BMC Cancer, 15
  • [46] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Komatsu, Yoshito
    Ishioka, Chikashi
    Shimada, Ken
    Yamada, Yasuhide
    Gamoh, Makio
    Sato, Atsushi
    Yamaguchi, Tatsuro
    Yuki, Satoshi
    Morita, Satoshi
    Takahashi, Shin
    Goto, Rei
    Kurihara, Minoru
    BMC CANCER, 2015, 15
  • [47] A randomized phase ll study of S-1 versus capecitabine as first-line chemotherapy in the elderly metastatic gastric cancer patients with/without poor performance status: clinical and pharmacogenetic results.
    Park, Sook Ryun
    Kong, Sun-Young
    Kim, Mi-Jung
    Kim, Min Kyeong
    Nam, Byung-Ho
    Choi, Mihee
    Park, Young-lee
    CANCER RESEARCH, 2013, 73 (08)
  • [48] Molecular biomarker study in randomized phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: XParTS IIb
    Tsuburaya, A.
    Nishikawa, K.
    Kobayashi, M.
    Kawada, J.
    Namikawa, T.
    Fukushima, R.
    Kojima, H.
    Tanabe, K.
    Yamaguchi, K.
    Yoshino, S.
    Takahashi, M.
    Hirabayashi, N.
    Sato, S.
    Nemoto, H.
    Rino, Y.
    Yoshikawa, T.
    Nakajima, J.
    Tan, P.
    Morita, S.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 59 - 60
  • [49] S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.
    Xu, Rui-hua
    Wang, Zhi-Qiang
    Shen, Lin
    Wang, Wei
    Lu, Jian-Wei
    Dai, Guanghai
    Xu, Jian-Ming
    Zhang, Yan-Qiao
    Chen, Xiao-Bing
    Deng, Yan-Hong
    Zhao, Yun-Bo
    Fan, Nan-Feng
    Yu, Gengsheng
    Liao, Wangjun
    Yuan, Xia
    Lin, You-En
    Liu, Guo-Long
    Zou, Qing-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Komatsu, Y.
    Takashima, A.
    Denda, T.
    Gamoh, M.
    Iwanaga, I.
    Shimodaira, H.
    Nakamura, M.
    Yamaguchi, T.
    Takahashi, H.
    Kobayashi, K.
    Tsuda, M.
    Kobayashi, Y.
    Baba, H.
    Kotake, M.
    Ishioka, C.
    Sato, A.
    Yuki, S.
    Morita, S.
    Takahashi, S.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2017, 28
12345